Posts

BridgeBio achondroplasia pill shows compelling growth and body proportionality benefit

on

How one biotech is using 'digital twins' to study a muscle disease therapy

on

Biogen trims Apellis R&D after $5.6B acquisition, focuses on Empaveli and Syfovre

on

EU Regulators Recommend Revoking Marketing Authorization for Amgen's Tavneos

on

FDA advisory panels set for Replimune and Capricor in July 2026

on

Enhertu Approved in the EU as First Tumor Agnostic HER2-Directed Therapy for Previously Treated HER2-Positive Metastatic Solid Tumors

on

How GSK's new CEO lined up a major buyout to start his time at the top

on

The Golden Triangle and the gaps: Rethinking UK biotech – recent industry dialogue and policy context

on

EU investigates Sanofi over alleged smear campaign against rival flu vaccine Fluad

on

Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears – 2026 analysis

on

Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production

on

BIO 2026: Making biotech IPOs great again and the forgotten pharma antitrust review

on

Recordati licenses Ionis drug

on

Merck KGaA buys Bio-Techne for $11.3 billion in largest deal in a decade

on

Friday Five: FDA steps up to counter China’s clinical‑trial edge, AbbVie buys Apogee, and psychedelics hype yields real data

on

BIO board met with national security, health officials on China’s biotech rise, CEO says (June 2026 news digestable summary)

on

Boehringer Ingelheim partners with Immunai on $15M AI‑driven T‑cell collaboration

on

FDA drops blood pressure device enforcement against Whoop

on

Gilead's Trodelvy Broad FDA Approval in Front-Line TNBC Fuels TROP2 ADC Market War

on

Ionis scores transformational FDA label expansion for Tryngolza

on

ADC Therapeutics cuts 17% of staff after 27 patient deaths in Zynlonta trial

on

Remix to take Nasdaq listing from Passage Bio in reverse merger for mRNA degrader platform

on

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering – June 24, 2026

on

Lilly offers up to $1.9B in new drug discovery deal with Abbisko

on

Ollin nets $330M to fund Phase 3 trials of Vabysmo challenger from China (OLN324)

on

No recent news about former employee suing BioNTech for cutting corners in pancreatic cancer trials found in current search results. The available information does not mention any such lawsuit or allegations related to BioNTech or pancreatic cancer trials involving a former employee. Thus, there is no recent news on this specific claim at this time.

on

Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues

on

Novartis pays Antares $105M to illuminate undruggable cancer targets

on

RQ Bio raises $115M to advance long‑acting flu prevention antibody into clinic

on

Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China

on

Definium Therapeutics Prices $700 Million Upsized Public Offering

on

Pfizer'

on